Xavier Matias-Guiu Guia

Martinez-Garcia, E; Lopez-Gil, C; Campoy, I; Vallve, J; Coll, E; Cabrera, S; Ramon Y Cajal, Santiago; Matias-Guiu, X; Van Oostrum, J; Reventos, J; Gil-Moreno, A; Colas, E

Advances in endometrial cancer protein biomarkers for use in the clinic

EXPERT REVIEW OF PROTEOMICS 15 81-99. 01/01/2018.

[doi:10.1080/14789450.2018.1410061]

Gatius, S; Cuevas, D; Fernandez, C; Roman-Canal, B; Adamoli, V; Piulats, JM; Eritja, N; Martin-Satue, M; Moreno-Bueno, G; Matias-Guiu, X

Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences

Pathobiology 85 35-40. 01/01/2018.

[doi:10.1159/000475529]

Eritja, N; Jove, M; Fasmer, KE; Gatius, S; Portero-Otin, M; Trovik, J; Krakstad, C; Sol, J; Pamplona, R; Haldorsen, IS; Matias-Guiu, X

Tumour-microenvironmental blood flow determines a metabolomic signature identifying lysophospholipids and resolvin D as biomarkers in endometrial cancer patients

Oncotarget 8 109018-109026. 12/12/2017.

[doi:10.18632/oncotarget.22558]

Depreeuw, J; Stelloo, E; Osse, EM; Creutzberg, CL; Nout, RA; Moisse, M; Garcia-Dios, DA; Dewaele, M; Willekens, K; Marine, JC; Matias-Guiu, X; Amant, F; Lambrechts, D; Bosse, T

Amplification of 1q32.1 Refines the Molecular Classification of Endometrial Carcinoma

CLINICAL CANCER RESEARCH 23 7232-7241. 01/12/2017.

[doi:10.1158/1078-0432.CCR-17-0566]

Martinez-Garcia, E; Lesur, A; Devis, L; Cabrera, S; Matias-Guiu, X; Hirschfeld, M; Asberger, J; van Oostrum, J; Casares de Cal MLÁ; Gomez-Tato, A; Reventos, J; Domon, B; Colas, E; Gil-Moreno, A

Targeted Proteomics Identifies Proteomic Signatures in Liquid Biopsies of the Endometrium to Diagnose Endometrial Cancer and Assist in the Prediction of the Optimal Surgical Treatment

CLINICAL CANCER RESEARCH 23 6458-6467. 01/11/2017.

[doi:10.1158/1078-0432.CCR-17-0474]

Garrido, P; Aldaz, A; Calleja, MA; de Alava, E; Lamas, MJ; Martin, M; Matias-Guiu, X; Palacios, J; Vera, R

Proposal for the Creation of a National Strategy for Precision Medicine in Cancer: a position statement of SEOM, SEAP and SEFH

FARMACIA HOSPITALARIA 41 688-691. 01/11/2017.

[doi:10.7399/fh.10877]

Novell, A; Morales, S; Valls J; Panades, MJ; Salud, A; Iglesias, E; Vilardell, F; Matias-Guiu, X; Llombart-Cussac, A

Novel biomarkers in primary breast core biopsies to predict poor response to neoadjuvant chemotherapy and appearance of metastases

HISTOLOGY AND HISTOPATHOLOGY 32 909-915. 01/09/2017.

[doi:10.14670/HH-11-849]

Le Gallo, M; Rudd, ML; Urick, ME; Hansen, NF; Zhang, S; NISC Comparative Sequencing Program; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW

Somatic Mutation Profiles of Clear Cell Endometrial Tumors Revealed by Whole Exome and Targeted Gene Sequencing

CANCER 123 3261-3268. 01/09/2017.

[doi:10.1002/cncr.30745]

Altadill, T; Dowdy, TM; Gill, K; Reques, A; Menon, SS; Moiola, CP; Lopez-Gil, C; Coll, E; Matias-Guiu, X; Cabrera, S; Garcia, A; Reventos, J; Byers, SW; Gil-Moreno, A; Cheema, AK; Colas, E

Metabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis

SCIENTIFIC REPORTS 7 8803-8803. 18/08/2017.

[doi:10.1038/s41598-017-09169-2]

Eritja, N; Felip, I; Dosil, MA; Vigezzi, L; Mirantes, C; Yeramian, A; Navaridas, R; Santacana, M; Llobet-Navas, D; Yoshimura, A; Nomura, M; Encinas, M; Matias-Guiu, X; Dolcet, X

A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-beta in mouse endometrium

CELL DEATH AND DIFFERENTIATION 24 1443-1458. 01/08/2017.

[doi:10.1038/cdd.2017.73]

Alsina-Sanchis, E; Figueras, A; Lahiguera, A; Gil-Martin, M; Pardo, B; Piulats, JM; Marti, L; Ponce, J; Matias-Guiu, X; Vidal, A; Villanueva, A; Viñals F

TGF Controls Ovarian Cancer Cell Proliferation

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 18 -. 01/08/2017.

[doi:10.3390/ijms18081658]

Alfon, J.; Erazo, T.; Perez-Montoyo, H.; Domenech, C.; Puig, T.; Segura, M. F.; Matias-Guiu, X.; Rodon, J.; Nadal, E.; Oaknin, A.; Gil, M.; Vidal, L.; Gascon, P.; Lizcano, J. M.

ABTL0812 AN AUTOPHAGY-ANTICANCER DRUG IN PHASE II CLINICAL TRIALS THAT INHIBITS PI3K/AKT/MTOR PATHWAY BY INDUCING TRIB3 EXPRESSION

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 121 30-30. 01/08/2017.